Department of Histology and Embryology, Medical College, Shaoxing City, China.
School of Life Science, Shaoxing University, Shaoxing City, China.
Mol Neurobiol. 2021 Jun;58(6):2803-2811. doi: 10.1007/s12035-021-02293-1. Epub 2021 Jan 27.
Traumatic brain injury (TBI) has both high morbidity and mortality rates and can negatively influence physical and mental health, while also causing extreme burden to both individual and society. Hitherto, there is no effective treatment for TBI because of the complexity of the brain anatomy and physiology. Currently, management strategies mainly focus on controlling inflammation after TBI. Tumor necrotizing factor alpha (TNF-α) plays a crucial role in neuroinflammation post-TBI. TNF-α acts as the initiator of downstream inflammatory signaling pathways, and its activation can trigger a series of inflammatory reactions. Infliximab is a monoclonal anti-TNF-α antibody that reduces inflammation. Herein, we review the latest findings pertaining to the role of TNF-α and infliximab in TBI. We seek to present a comprehensive clinical application prospect of infliximab in TBI and, thus, discuss potential strategies of infliximab in treating TBI.
创伤性脑损伤（TBI）具有高发病率和死亡率，会对身心健康产生负面影响，同时给个人和社会带来极大负担。迄今为止，由于大脑解剖和生理学的复杂性，TBI 还没有有效的治疗方法。目前，TBI 后的管理策略主要集中在控制炎症上。肿瘤坏死因子-α（TNF-α）在 TBI 后的神经炎症中起着关键作用。TNF-α 作为下游炎症信号通路的启动子，其激活可以引发一系列炎症反应。英夫利昔单抗是一种抗 TNF-α 的单克隆抗体，可减轻炎症。本文综述了 TNF-α 和英夫利昔单抗在 TBI 中的作用的最新研究结果。我们旨在提出英夫利昔单抗在 TBI 中的临床应用前景，并探讨英夫利昔单抗治疗 TBI 的潜在策略。
